8-K: BioLife Solutions Reports Strong Q1 2025 Results, Driven by Cell Processing Revenue Growth

BioLife Solutions announces a 30% increase in total revenue for Q1 2025, driven by a 33% surge in cell processing revenue.

Summary

• BioLife Solutions reported a 30% increase in total revenue for the first quarter of 2025, reaching $23.9 million compared to $18.4 million in Q1 2024.
• Cell Processing platform revenue grew by 33% to $21.6 million.
• The company's GAAP gross margin remained consistent at 63%, while the non-GAAP adjusted gross margin also stayed at 66%.
• BioLife Solutions reported a GAAP net loss of $0.4 million, an improvement from the $3.2 million loss in the same period last year.
• Adjusted EBITDA for Q1 2025 was $5.7 million, representing 24% of revenue, compared to $2.6 million, or 14% of revenue, in Q1 2024.
• As of March 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $107.6 million.
• BioLife Solutions is affirming its 2025 revenue guidance of $95.5 million to $99.0 million, representing growth of 16% to 20% compared with 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability metrics, and a strategic acquisition. The company's reaffirmed guidance and management's confidence contribute to the positive sentiment.

Positives

• Significant revenue growth in the Cell Processing platform, indicating strong market demand.
• Improved net loss compared to the previous year, suggesting better cost management.
• Strong adjusted EBITDA margin, reflecting operational efficiency.
• Healthy cash position, providing financial flexibility for future investments.
• Strategic acquisition of PanTHERA CryoSolutions, enhancing the company's product offerings.
• Affirmed revenue guidance for 2025, demonstrating confidence in future performance.

Negatives

• The company still reported a GAAP net loss of $0.4 million for the quarter.
• evo and Thaw platform revenue experienced a slight sequential decrease of 3%.

Risks

• The company acknowledges navigating a dynamic operating environment, which could impact future performance.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

BioLife Solutions is affirming its 2025 revenue guidance of $95.5 million to $99.0 million, expecting continued growth and expansion of adjusted EBITDA margin.

Management Comments

• Roderick de Greef, Chairman and CEO, stated that the company is off to a strong start to 2025, delivering 33% year-over-year growth in cell processing revenue.
• He also highlighted the expansion of adjusted EBITDA margin and the company's disciplined approach to capital allocation.
• Management remains confident in their outlook for 2025 and their ability to deliver growth and create sustained value for shareholders.

Industry Context

BioLife Solutions operates in the cell and gene therapy (CGT) market, which is experiencing significant growth. The company's focus on cell processing tools and services positions it to benefit from the increasing demand for these solutions in the development and commercialization of new therapies.

Comparison to Industry Standards

• While specific competitor data isn't provided, BioLife's 33% growth in cell processing revenue suggests a strong performance compared to the overall growth rate of the CGT market.
• Companies like Thermo Fisher Scientific and Danaher also provide solutions for the CGT market, but BioLife focuses specifically on cell processing, giving them a specialized position.
• The adjusted EBITDA margin of 24% indicates efficient operations and profitability compared to industry averages.

Stakeholder Impact

• Shareholders can expect continued growth and value creation.
• Employees may benefit from the company's expansion and strategic initiatives.
• Customers will have access to enhanced cell processing solutions through the acquisition of PanTHERA CryoSolutions.

Next Steps

• Management will discuss the financial results and provide a business update during a conference call and live webcast.
• The company will continue to advance innovative solutions to the growing CGT market, both organically and inorganically.

Key Dates

Keywords

BioLife Solutions, cell processing, biopreservation, cell and gene therapy, CGT, revenue, EBITDA, financial results, PanTHERA CryoSolutions, acquisition